Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis

Akira Nishi, Kyosuke Sawada, Hiroyuki Uchida, Masaru Mimura, Hiroyoshi Takeuchi

研究成果: Review article査読

抄録

Although several randomized controlled trials (RCTs) have compared the effectiveness, efficacy, and safety of antipsychotic monotherapy (APM) versus placebo in patients with major depressive disorder (MDD), no meta-analysis has examined this topic. We conducted a systematic literature search using MEDLINE and Embase to identify relevant RCTs and performed a meta-analysis to compare the following outcomes between APM and placebo: response and remission rates, study discontinuation due to all causes, lack of efficacy, and adverse events, changes in total scores on depression severity scales, and individual adverse event rates. A total of 13 studies were identified, with 14 comparisons involving 3,197 participants that met the eligibility criteria. There were significant differences between APM and placebo in response and remission rates and changes in the primary depression severity scale in favor of APM, and study discontinuation due to adverse events and several individual adverse events in favor of placebo. No significant difference was observed in discontinuation due to all causes. APM could have antidepressant effects in the acute phase of MDD, although clinicians should be aware of an increased risk of some adverse events.

本文言語English
ページ(範囲)5-17
ページ数13
ジャーナルPharmacopsychiatry
56
1
DOI
出版ステータスPublished - 2023 1月 1

ASJC Scopus subject areas

  • 精神医学および精神衛生
  • 薬理学(医学)

フィンガープリント

「Antipsychotic Monotherapy for Major Depressive Disorder: A Systematic Review and Meta-Analysis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル